Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (9987)	5/16/1999 1:30:00 AM
From: Tharos	Read Replies (2) \| Respond to of 17367

George, I thought the US Congress changed the promotion aspect of off label use. I know some states have changed their laws.

To: aknahow who wrote (9987)	5/16/1999 9:05:00 AM
From: Robert K.	Respond to of 17367

dent.ucla.edu:81/perio/members/neutrophils/neutrophils2.html

To: aknahow who wrote (9987)	5/16/1999 4:39:00 PM
From: RXGOLF	Respond to of 17367

<<Off label use can and will occur. Xoma will not be able to promote it. As it occurs and independent research indicates value for other indications Xoma will be able to distribute this information to potential decision makers. >> Yes George, XOMA will not be able to print up the "possible" use for BPI and pass them out to Dr's. But they can reprint results and put those results in the Dr's hands as food for thought. It is my understanding that the sales reps can't orally detail the Dr on the unapproved uses. It is also my understanding that sales reps DO detail(not officially I'm sure<g>) on unapproved uses. Reps that have been in an area for a number of years often have a relationship with the "favorite Dr's" that allow them to discuss such things. IMO, Greg